Axsome Therapeutics, Inc. Income Statement

Income Statement Dec2013 Dec2014 Dec2015 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue -0.14M-0.27M-0.70M50.04M270.60M385.69M
Cost of Revenue 5.20M26.07M33.30M
Gross Profit 44.84M244.53M352.39M
Operating items
Amortization - Intangibles 4.14M6.38M6.39M
Research & Development 1.54M4.28M6.78M58.06M57.95M97.94M187.08M
Selling, General & Administrative 0.30M1.39M2.42M66.65M159.25M323.12M411.36M
Other Operating Expenses -0.28M-0.21M81.36M67.82M
Operating Expenses 1.84M5.67M9.20M124.71M229.84M502.43M666.25M
Operating Income -1.84M-5.67M-9.20M-124.71M-179.80M-231.82M-280.56M
EBIT -1.84M-5.67M-9.20M-124.71M-179.80M-231.82M-280.56M
Non-operating items
Interest & Investment Income -5.70M-7.33M-6.45M-6.57M
Other Non Operating Income -2.87M-2.44M
Net income details
EBT -1.98M-5.94M-9.90M-130.40M-187.13M-238.28M-287.13M
Tax Provisions 0.96M0.09M
Profit After Tax 2.17M-6.00M-12.21M-130.40M-187.13M-239.24M-287.22M
Income from Continuing Operations -1.98M-5.94M-9.90M-130.40M-187.13M-239.24M-287.22M
Consolidated Net Income -1.98M-5.94M-9.90M-130.40M-187.13M-239.24M-287.22M
Income towards Parent Company -1.98M-5.94M-9.90M-130.40M-187.13M-239.24M-287.22M
Net Income towards Common Stockholders -1.98M-5.94M-9.90M-130.40M-187.13M-239.24M-287.22M
Additional items
EPS (Basic) -0.56-3.47-4.60-5.27-5.99
EPS (Weighted Average and Diluted) -3.47-4.60-5.27-5.99
Shares Outstanding (Weighted Average) 17.72M37.69M43.43M47.32M48.46M
Shares Outstanding (Diluted Average) 40.66M45.43M47.91M
EBITDA -1.84M-5.67M-9.20M-124.71M-179.80M-231.82M-280.56M
Interest Expenses 0.14M0.27M0.70M